ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Moffitt Doctor Publishes Leukemia Drug Breakthrough Study in New England Journal of Medicine
List, MD, leader of the Hematologic Malignancies Program at the H. Lee Moffitt Cancer Center & Research Institute,
recently conducted a phase I/II trial of the experimental drug Revlimid showing promise as an innovative way to treat
patients with myelodysplastic syndrome (MDS), a form of pre-leukemia. Given in pill form, Revlimid simultaneously blocks the
growth of new blood vessels that nourish tumors (anti-angiogenesis) and stimulates the immune system to fight cancer cells.
The study is reported in the Feb.10 issue of the New England Journal of Medicine.
Nearly 90 percent of MDS patients are anemic and require regular transfusions of red cells. In this study, 91 percent of the
MDS patients with a chromosome abnormality named 5q minus syndrome became transfusion independent. The defective 5q
chromosome abnormality may be linked to other serious cancers, including leukemias and small cell lung cancer. In another
finding of the same study, all the patients with the 5q deletion who became transfusion independent also went into
cytogenetic remission, meaning that the chromosome abnormality disappeared.
List initially developed the phase I clinical trial of Revlimid for treatment of MDS following his laboratory observations
that the agent improved the growth of red blood cell precursors from MDS bone marrow. Celgene will submit the seminal
findings of List's phase I trial - along with data from two recent confirmatory phase II clinical trials performed nationwide
involving more than 350 patients with red blood cell transfusion-dependent MDS - to the U.S. Food and Drug Administration in
a new drug application (NDA) for Revlimid as an innovative approach to treat the anemia of MDS patients with the 5q minus
deletion.
In 2001, the National Cancer Institute awarded Moffitt the status of a Comprehensive Cancer Center in recognition of its
excellence in research and contributions to clinical trials, prevention and cancer control. Additionally, Moffitt is a member
of the National Comprehensive Cancer Network, a prestigious alliance of the country's leading cancer centers, and is listed
in the U.S. News & World Report as one of the top cancer hospitals in America. Moffitt's sole mission is to contribute to the
prevention and cure of cancer.
Jean C. Johnson, Media Relations Specialist
Public Relations & Marketing Department
Moffitt Cancer Center
12902 Magnolia Drive, MBC/PR
Tampa, FL 33612
Work: 813-975-7896
Fax: 813-632-1380/813-558-4808
Email: Johnsojc@moffitt.usf.edu
For more information, contact:
MediaRelations@moffitt.usf.edu
(813) 632-1478
View drug information on Revlimid.
Moffitt Doctor publicã leucemiei de droguri Breakthrough Studiul în New England Journal of Medicine - Moffitt Doctor Publishes Leukemia Drug Breakthrough Study in New England Journal of Medicine - articole medicale engleza - startsanatate